Across TCGA pan-cancer cohorts, ANKS1B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ANKS1B data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ANKS1B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANKS1B expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM are the cancer types where ANKS1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.840	0.693	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: ANKS1B tumor-vs-normal RNA expression · all ANKS1B data types